Apotex Rolls Out Pegfilgrastim A Year After Canadian Approval

Apotex is rolling out its Lapelga pegfilgrastim biosimilar across Canada, almost a year after securing marketing authorization. But Mylan is seeking local reimbursement for its Fulphila alternative.

Fireworks
Apobiologix is launching its Lapelga pegfilgrastim biosimilar across Canada • Source: Shutterstock

More from Biosimilars

More from Products